Trial Profile
Trial of Cellceutix' topical defensin-mimetic compound for induction of remission of ulcerative proctitis and ulcerative proctosigmoiditis
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2015
Price :
$35
*
At a glance
- Drugs Defensin stimulants (Primary)
- Indications Ulcerative proctitis; Ulcerative proctosigmoiditis
- Focus Adverse reactions
- Sponsors Innovation Pharmaceuticals
- 29 Jan 2015 New trial record
- 26 Jan 2015 Cellceutix is submitting a request to the US FDA for a pre-IND meeting, with the goal of initiating this trial in 2015, according to a media release.